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A COL4A3 gene mutation and post-transplant anti-a3(IV) collagen 
alloantibodies in Alport syndrome. The X-Iinked Alport syndrome is 
associated with mutations and deletions in COL4A5 gene, one of six genes 
which constitute the ^-chains of type IV collagen in basement membranes. 
The autosomal recessive form of Alport syndrome is characterized by 
mutations and deletions in the COL4A3 and COL4A4 genes. A  fraction of 
Alport patients who undergo renal transplantation develop anti-glomeru- 
lar basement membrane (GBM) nephritis, which results in loss of the 
renal allograft function. Recently, the target for alloantibodies from an 
X-linked Alport patient with complete COL4A5 gene deletion was 
determined to be the a3 chain of type IV collagen. The present study 
characterized the post-transplant alloantibodies from an autosomal reces­
sive Alport patient with anti-GBM glomerulonephritis and a COL4A3 
gene mutation which predicted a loss of 85% of the a3(IV) NCI domain. 
The specificity of these new antibodies were studied using glomerular 
basement membrane constituents and recombinant type IV collagen 
domains. The results establish the target for the alloantibodies, from an 
autosomal recessive Alport patient with COL4A3 deletion as principally 
the cy3(IV) collagen chain, similar to the post-transplant alloantibodies 
from X-linked Alport patients with COL4A5 gene deletions, The absence 
of cy3(IV) chain in the GBM of patients with both these forms of Alport 
syndrome, due either to a failure of synthesis or a failure of assembly, 
presumably leads to a loss of immunologic tolerance for the a3(IV) NCI 
domain in transplanted allografts.
Alport syndrome is a progressive hereditary kidney disease 
characterized by hematuria, sensorineural hearing loss, and ocular 
lesions with structural defects in GBM [1-3]. The disease is 
primarily X chromosome-linked, but autosomal forms of inheri­
tance are also known [4]. The X-linked syndrome is associated 
with mutations and deletions in COL4A5 gene, which encodes the 
a5(IV) chain, one of six genetically distinct type IV collagen gene 
products [3, 5-7]. The rare autosomal forms of Alport syndrome 
are associated with recessive mutations in the COL4A3 and 
COL4A4 genes which encode the a3(IV) and a4(IV) chains, 
respectively [8, 9].
Anti-GBM disease appears in 5 to 10% of Alport patients who
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receive a kidney transplant following the development of renal 
failure. In the recent years, insight into the structural nature of the 
defect in Alport GBM has been determined by establishing the 
target of anti-GBM alloantibodies produced by these patients 
[10»14]. Alloantibodies from seven post-transplant Alport pa­
tients, for example, were found reactive to the NCI domain of 
type IV collagen [9-14]. Three of these antisera, under closer 
scrutiny, did not bind to Alport GBM and were found reactive to
the «3(IV) chain [11]. Recently, post-transplant anti-GBM alloan-
b
tibodies harvested from a X-linked Alport patient with complete 
COL4A5 gene deletion was characterized [15], These alloantibod­
ies were also specifically targeted to the a3(IV) chain [15]. This 
study suggested a pivotal role for the «5 (IV) chain in the secretion 
or assembly of type IV collagen co-expressing the a3(IV) moiety.
The present study characterizes the target antigen for the 
post-transplant alloantibodies from an autosomal recessive Alport 
patient with COL4A3 gene deletion.
Methods
Patient histoty
The case history of family VB is described elsewhere [8,9], The 
affected female had hematuria from age 4, and typical ultrastruc- 
tural lesions of Alport syndrome on electron microscopy of a renal 
biopsy and sensorineural deafness. Renal function deteriorated 
gradually until hemodialysis was started at age 9. She received a 
renal allograft at age 10 and developed anti-GBM nephritis six 
months later. Her brother has hematuria, deafness, and deterio­
rating renal function. The parents have no hematuria, proteinuria 
or deafness. There is no known consanguinity, but the parents and 
their known ancestors originate from the same small village in the 
Netherlands. The affected female in family VB has a deletion of 
last 198 amino acids of the a3(IV) chain. This was predicted to 
result in a chain termination after 33 amino acids of the NCI 
domain.
GBM antigens and analytic assays
The preparation of the GBM constituents, fibronectin, laminin, 
heparan sulfate proteoglycan, entactin, 7 S domain of type IV 
collagen, pepsin solubilized triple helical fragments of type IV 
collagen and NCI domains of type IV collagen a-chains was 
described previously [16]. Recombinant human type IV collagen 
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Fig. 2. Identification GBM constituent(s) that hind to the Alport alloanti­
bodies. The various GBM constituents were F, fibronectin, L, Iaminin, 
HSP, heparan sulfate proteoglycan, E, entactin, 7 S, 7 S domain of type IV 
collagen, pepsin solubilized TIT, triple helical fragments of type IV 
collagen and dimers and monomers of NCI domains of type IV collagen 
a-chains. The dilution of alloantibodies was 1:500. The control serum did 
not bind to any of the GBM constituents.
upon incubation with the circulating alloantibodies (Fig. IB). 
These results suggest that additional binding sites for the alloan- 
tisera in the transplanted kidney are accessible in vitro compared 
to in vivo, and that there is a structural difference within the GBM 
of the Alport and transplanted kidney.
Specificity o f alloantibodies to GBM constituents and bovine type
IV  collagen domains
The specificity of post-transplant anti-GBM alloantibodies from 
an autosomal recessive Alport patient with COL4A3 deletion was 
determined using bovine GBM constituents and bovine NCI 
domains of the a-chains of type IV collagen. The GBM constit­
uents used were: fibronectin, Iaminin, heparan sulfate proteogly­
can and entactin. Bovine type IV collagen domains used were: 7 S 
domain of type IV collagen, pepsin solubilized triple helical 
fragments of type IV collagen and dimeric and monomeric NCI 
domains of type IV collagen a-chains. The alloantibodies reacted 
specifically to the a3(IV) NCI containing dimers and a3(IV) NCI 
monomers (Fig. 2).
Specificity o f the alloantibodies to bovine type IV  collagen NCI 
domains by one- and two-dimensional gel electrophoresis
and immunoblotting
The alloantibodies from the affected patient were analyzed by 
one- and two-dimensional gel electrophoresis and immunoblot­
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(D1-dimers) and a3, «4, a5 and a6 NCI dimers (D2-dimers). At 
the NCI hexamer level, the alloantibodies bound strongly to the 
54 kDa dimers, a 28 kDa monomer, and very faintly to a 26 kDa 
monomer (data not shown), as visualized by one dimensional 
immunoblotting. To further evaluate this binding in terms of type 
IV collagen a-chains, we performed two-dimensional gel electro­
phoresis and immunoblotting using bovine NCI hexamer. The 
bovine NCI hexamer was used since all the spots originating from 
the six a-chains have been identified based on their pi and 
molecular weight by two-dimensional gel electrophoresis (Identi­
fication of a l-a5 spots was previously reported by Gun war et al 
[16]. The monomeric and dimeric spots originating from the 
a6(IV) was recently identified. R. Kalluri, J. Zhou, and B.G. 
Hudson, unpublished data.) The alloantibodies reacted specifi­
cally to the a3(IV) NCI dimers and monomers, identical to the 
spots that bind to anti-a3(IV) chain specific antibodies as previ­
ously described [16] (Fig. 3). No reactivity was found with the 
al(IV), a2(IV), a4(IV), a5(IV) and aó(IV) NCI dimers and 
monomers. Additionally, the alloantibodies did not react to the al 
4* a2(IV) NCI dimers and monomers, as evaluated by one 
dimensional immunoblotting (data not shown). These results 
establish the target for the alloantibodies as the a3(IV) chain of 
bovine type IV collagen.
Inhibition ELISA
Type IV collagen a-chain specific antibodies were used to 
perform inhibition ELISA using bovine NCI hexamer as the 
antigen. The NCI hexamer was allowed to bind with one of the six 
a-chain specific antibodies and subsequently followed with the 
Alport alloantibodies. The anti-a3(IV) chain specific antibodies 
inhibited the alloantibodies binding (Figs. 4 A and B). All the 
other antibodies did not inhibit the alloantibodies binding to the 
NCI hexamer. These results establish the alloantibodies as anti- 
a3(IV)NCl antibodies.
Specificity o f the alloantibodies to the recombinant human type IV
collagen NCI domains
The alloantibodies were further analyzed for their capacity to 
bind recombinant human type IV collagen NCI domains (al to 
a5). The alloantibodies reacted very strongly to the recombinant 
a3(IV) NCI (Fig. 5) and to a very minor degree with the 
recombinant a5(lV)NCl domain (1:200 dilution of alloantisera, 
lost at 1:500). The weak reactivity with the a5(IV)NCl may be a 
cross-reactivity phenomenon, due to the high homology between 
the NCI domains [24]. Alternatively, the weak binding may be 
specific reactivity only observed with human a5(IV)NCl se­
quence; repeating the gel with half the amount of target NCI 
domains eliminated evidence of weak binding while preserving the 
strong reactivity to a3. These results establish the principal target 
for post-transplant anti-GBM nephritis in an Alport patient with 
COL4A3 gene deletion as the a3 chain of type IV collagen.
Discussion
In several previous studies, the target for X-linked Alport 
alloantibodies was identified as the NCI domain of type IV 
collagen [10-14]. Hudson et al have shown the target for three 
post-transplant alloantibodies as the a3(IV) chain [1.1]. Kleppel et 
al implicated the a5(IV) chain as a target for alloantibodies in 
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